@entity27 ( @entity27 ) may manifest in a number of ways from subtle intrusion into daily life to profound @entity25 , snoring, witnessed @entity386 and other classic symptoms. Although there is increasing evidence suggesting @entity27 can adversely affect health in a variety of ways, this disorder remains underdiagnosed. The most well-escribed health consequences of @entity27 relate to the cardiovascular system. @entity101 and @entity943 have a strong association with @entity27 , and evidence suggests that treatment of @entity27 in @entity1 with refractory @entity101 and in @entity1 planning cardioversion for @entity955 may be of particularly importance. Significant associations between @entity712 and @entity27 as well as complex @entity387 have also been well-described. @entity1504 , impaired neurocognition, and poorly controlled @entity1316 are also associated with in @entity27 . Therapy for @entity27 may ameliorate @entity731 progression and improve outcomes @entity64 ( @entity64 ). @entity27 should be considered in @entity1 complaining of poor concentration at work, actual or near-miss motor vehicle accidents, and @entity1 with severe @entity25 as a component of their co-morbid @entity1316 . The metabolic impact of @entity27 has also been studied, particularly in relation to @entity413 homeostasis. Also of interest is the potential impact @entity27 has on lipid metabolism. The adverse effect untreated @entity27 has on @entity413 tolerance and lipid levels has led to the suggestion that @entity27 is yet another constituent of the @entity209 . Some of these metabolic derangements may be related to the adverse effects untreated @entity27 has on hepatic health. The cardiovascular, neurocognitive, and metabolic manifestations of @entity27 can have a significant impact on @entity1 health and quality of life. In many instances, evidence exists that therapy not only improves outcomes in general, but also modifies the severity of co-morbid disease. To mitigate the long-term sequela of this disease, providers should be aware of the subtle manifestations of @entity27 and order appropriate testing as necessary.

Clinical manifestations of XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity712 :: ('MESH:D006333', 'Disease') :: ['heart failure'] @entity64 :: ('MESH:D020521', 'Disease') :: ['post-cerebrovascular accident', 'CVA'] @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension', 'Hypertension'] @entity387 :: ('MESH:D012891', 'Disease') :: ['sleep apnea'] @entity209 :: ('MESH:D008659', 'Disease') :: ['metabolic syndrome'] @entity27 :: ('MESH:D020181', 'Disease') :: ['Obstructive sleep apnea', 'OSA'] @entity1504 :: ('MESH:D002561', 'Disease') :: ['Cerebrovascular insult'] @entity1316 :: ('MESH:D019964', 'Disease') :: ['mood disorder', 'mood disorders'] @entity955 :: ('MESH:D001281', 'Disease') :: ['atrial fibrillation'] @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose'] @entity731 :: ('MESH:D050197', 'Disease') :: ['atherosclerotic'] @entity943 :: ('MESH:D001145', 'Disease') :: ['arrhythmias'] @entity25 :: ('MESH:D012893', 'Disease') :: ['sleepiness'] @entity386 :: ('MESH:D001049', 'Disease') :: ['apneas']
@entity387 :: (MESH:D012891,Disease) :: ['sleep apnea']
